Business Wire

GETT

19.4.2021 15:02:06 CEST | Business Wire | Press release

Share
Gett Strengthens Global Technology Platform to Combine Corporate Fleets and Ride-Hailing

Gett, the leading innovator in corporate Ground Transportation Management (GTM), continues to expand its marketplace of global partner fleets onto one technology platform to provide broad geographic coverage and service levels for enterprise clients.

Gett launched one of the first-ever on-demand corporate travel services in 2010, attracting Google and Disney among its first clients. With over 10 years of expertise designing seamless ground transportation experiences, Gett reduces corporate spend on ground transportation for its clients by up to 45% by offering price comparison, enforcement of travel policy compliance and optimization of back-office processes. Gett’s platform also provides other benefits, including a seamless rider experience for employers prioritizing the safety and security of their people returning to business travel following Covid-19 lockdown.

The expansion of Gett’s global platform coincides with a new supply partnership, as US taxi and e-fleet operator Curb Mobility partners with Gett and joins a portfolio of operating fleets including Lyft and Ola to access incremental high quality demand. This partnership will enable Gett to extend its presence to 65 cities in the US, expanding Gett’s marketplace to include yellow cabs as well as Gett’s existing range of vehicles and partner fleets. Bringing corporate customers a range of licensed vehicles, this new partnership supports increased demand for ground transportation as business professionals seek enhanced safety in light of the Covid-19 pandemic with the resumption of business travel.

Partner fleets already accounted for approximately one-third of B2B rides taken on Gett in Q1 2021. With the addition of Curb, and momentum in Gett’s transition from ride-hailing to an enterprise marketplace software platform, it is expected that partner fleets will represent the majority of Gett’s B2B rides globally by the end of 2021.

Gett’s largest markets are becoming lead indicators for the ground transportation and global corporate travel industries, with the progress of Covid-19 vaccination programmes in Israel and the UK. In Q1 2021, global transactions on Gett’s platform by corporate users returned to approximately 80% of the volumes seen for the corresponding period in 2020 ahead of Covid-19 lockdown restrictions. In this time period, individual markets also experienced corporate passenger volumes in excess of 2020 peaks.

Dave Waiser, CEO and co-founder of Gett commented : “Today’s partnership cements Gett’s position as a technology platform focused on corporate Ground Transportation Management (GTM), where spend is worth $79.6B globally. In recent years, we have become the GTM category leader, serving over a quarter of Fortune 500 companies.

“Our cloud-based software aggregates existing transportation providers into a single platform, helping businesses effectively manage all of their ground transportation spend. Additionally, it can expand companies’ coverage and reach by connecting them to a global transportation grid.

“We believe that bringing corporate fleets and ride-hailing companies together on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saves corporations both time and money.”

Amos Tamam, CEO at Curb commented : “As cities across the U.S. prepare for the return of international travel, our partnership with Gett will create new income opportunities for local drivers and ensure Gett's business users have access to the same safe, reliable transportation options trusted by locals. By integrating with platforms like Gett, we're aiming to make taxis more ubiquitous online by opening up new digital avenues for today’s consumers and businesses to find and book taxis.”

ENDS

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye